HAE HAEMONETICS CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 313143 · Fiscal year ends 04/03
Financial factors as of 2026-09-26 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.1%
TTM net income YoY-38.2%
TTM EPS YoY-33.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR-6.8%
Margins
Gross margin59.6%
Operating margin12.8%
Net margin7.5%
FCF margin21.6%
EBITDA margin20.7%
Returns
ROE11.9%
ROA4.3%
ROIC (approx.)7.3%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets62.7%
Debt / equity1.25x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.32x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-28 | FY20252025-03-29 |
|---|---|---|
| Income statement | ||
| Revenue | $1.33B | $1.36B |
| Cost of revenue | $546.44M | $611.87M |
| Gross profit | $787.59M | $748.96M |
| R&D expense | $59.77M | $62.72M |
| SG&A expense | $442.42M | $436.79M |
| Operating income | $156.73M | $221.82M |
| Interest expense | $19.30M | $35.90M |
| Pretax income | $128.03M | $212.07M |
| Income tax | $30.72M | $44.39M |
| Net income | $97.31M | $167.68M |
| EBITDA | $268.45M | $337.40M |
| EPS (basic) | 2.06 | 3.33 |
| EPS (diluted) | 2.05 | 3.31 |
| Weighted avg. shares (diluted) | 47.35M | 50.73M |
| Balance sheet | ||
| Cash & equivalents | $245.44M | $306.76M |
| Receivables | $216.85M | $202.66M |
| Inventory | $306.37M | $365.14M |
| Current assets | $834.88M | $934.98M |
| PP&E, net | $305.76M | $284.05M |
| Goodwill | $656.37M | $604.27M |
| Intangibles | $447.65M | $455.74M |
| Total assets | $2.40B | $2.45B |
| Current liabilities | $282.60M | $578.11M |
| Short-term debt | $5.01M | $303.56M |
| Long-term debt | $1.22B | $921.23M |
| Total debt | $1.22B | $1.22B |
| Total liabilities | $1.60B | $1.63B |
| Shareholders' equity | $796.32M | $820.84M |
| Net debt | $979.14M | $918.02M |
| Shares outstanding | 45.25M | 48.22M |
| Cash flow statement | ||
| Operating cash flow | $293.22M | $181.72M |
| Capital expenditure | $32.78M | $39.28M |
| Free cash flow | $260.44M | $142.45M |
| Investing cash flow | -$179.55M | -$161.90M |
| Financing cash flow | -$178.46M | $108.82M |
| Depreciation & amortization | $111.72M | $115.59M |
| Stock-based compensation | $33.83M | $29.64M |
| Share buybacks | $175.00M | $225.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.